The Office of Technology Licensing was established in 1970 to transfer technologies developed at Stanford. Find out more about OTL's history, mission, staff, and statistics.

Login to TechFinder » 

Additional εPKC Activator Peptides to Provide Cardioprotection


Stanford Reference:

06-342


Abstract


Dr. Daria Mochly-Rosen and colleagues have identified additional εPKC activator peptides that can provide cardioprotection from ischemic damage. Also included are εPKC inhibitor peptides.

Stage of Research
In an ex vivo model of ischemia and reperfusion, the εPKC activator peptides were cardioprotective.


Applications


  • Cardioprotection from damage caused by ischemia:
    • Heart transplant

Advantages


  • Peptides are selective for εPKC

Publications



Related Web Links



Innovators & Portfolio



Patent Status



Date Released

 8/26/2013
 

Licensing Contact


Sara Nakashima, Licensing Associate
650 725 9115 (Direct)
Login to Request Information

[-] Map/Timeline

93-168 Peptides That Modulate Interaction Between PKC and RACK
96-086 Novel method to Deliver Biopolymers into Cells
96-103 εPKC Agonists to Provide Cardioprotection

more technologies

Related Keywords


ischemia   protein kinase inhibitors   protein kinase   ischemic damage   PKC   transplantation   cardioprotection   cardiovascular   epsilon protein kinase C   ischemic   protein kinase c   therapeutic: peptides   
 

   

  

Also of Interest...
93-168 Peptides That Modulate Interaction Between PKC and RACK
96-086 Novel method to Deliver Biopolymers into Cells
96-103 εPKC Agonists to Provide Cardioprotection

Recently Viewed...
S06-342 Additional εPKC Activator Peptides to Provide Cardioprotection